Lilly denies NY Times Zyprexa report
Eli Lilly has denied the assertions of a recent New York Times article alleging that incoming CEO John Lechleiter encouraged off-label promotion of the company's embattled schizophrenia treatment Zyprexa (olanzapine) in an e-mail he sent in 2003.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.